Hippel indicated that overall Q2 organic growth is anticipated to be consistent with Q1, with continued strength in pharma, renewed growth in China, a rebound in spatial biology, and gradual ...

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, ...

MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution ...

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Learn more Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth and ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest deal in over a decade.

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.